Neuro

Hudson Mind Launches Two-Step Nervous System Treatment to Relieve Anxiety

Retrieved on: 
Dienstag, Mai 7, 2024
Brain, Digestion, Sleep, SGB, Syndrome, Transcranial magnetic stimulation, Research, Heart rate, Parasympathetic nervous system, Nervous system, Pressure, Autonomic nervous system, Sympathetic nervous system, Irritability, Neuro, Hydrodissection, Anxiety, Vagus nerve, Medical imaging

NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Hudson Mind, an interventional mental health clinic in New York City, launched their specialized Neuro Reset treatment, which drastically reduces symptoms of chronic anxiety.
  • Having administered thousands of SGBs, Hudson founder and Chief Medical Officer Dr. Jonathann Kuo developed the Neuro Reset as a means of boosting support for the total nervous system.
  • "To overcome the ongoing cycle of stress that modern life perpetuates, we have to support the total nervous system.
  • Neuro Reset joins a range of clinically-proven interventions at Hudson Mind, including IV ketamine therapy and Transcranial Magnetic Stimulation.

Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Retrieved on: 
Donnerstag, April 18, 2024
American Academy, Mass, Hospital, Stabilizer, White matter, PET, EDSS, Human, Patient, MFIS, Fatigue, DSM-IV codes, Harvard Medical School, Biomarker, Annual general meeting, Associate, Microsoft Access, Neuro, PIRA, Medical imaging

The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.

Key Points: 
  • The presentation includes new, encouraging quantitative imaging data from foralumab’s intermediate- size patient population Expanded Access Program.
  • Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented, “Tiziana is taking a leadership role in focusing on this subset of progressive MS where there are no effective treatments.
  • The study is designed to be open-label and part of the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.
  • This trial ( NCT06292923 ) is important because if the potential to slow disease progression is demonstrated this would align with early treatment intervention.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024

Retrieved on: 
Mittwoch, Mai 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Doctor of Philosophy, PFS, Paranal Observatory, Table, License, Summit, Investment, ELCC, Progression-free survival, Research, Intraparenchymal hemorrhage, Immunotherapy, Trial of the century, Webcast, Cohort, Forecasting, PD-1, NGS, TKI, Patient, GRAIL, Brain, SMMT, Neoplasm, EGFR, VEGF, GAAP, Royal institute, Neuro, Lung cancer, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2024.
  • In January 2024, followed by a presentation at ELCC 2024 in March 2024, Akeso announced updates from its Phase II AK112-201 trial data.
  • Also at ELCC 2024, Summit and Akeso highlighted promising ivonescimab Phase II data in NSCLC patients with brain metastases.
  • Operating cash outflow for the three months ended March 31, 2024 and 2023 was $30.1 million and $13.1 million, respectively.

Anova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM Grant

Retrieved on: 
Mittwoch, Mai 1, 2024
Other Health, Software, Research, Pharmaceutical, Philanthropy, Oncology, Technology, Foundation, Science, Biotechnology, Other Science, Health, FDA, University, UCSD, BTRC, Regenerative medicine, HGG, University of California, Partnership, Doctor of Philosophy, CIRM, UCSF, Patient, Analysis of variance, SOC, Enterprise, USC, Neuro

Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

Key Points: 
  • Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San Francisco (UCSF), University of California at San Diego (UCSD), the University of Southern California (USC) and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine (CIRM) grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.
  • DGM7 has been shown to be associated with increased overall survival with treatment of recurrent HGG, via retrospective analysis.
  • Anova was approached to assist with the development of the product and was instrumental organizing leading neuro-scientists, developing the study plans, securing FDA approval, preparing the CIRM application, and securing the ultimate CIRM award.
  • The Phase 1/2a clinical trial is a multicenter, open-label study designed to confirm whether treatment DB107, when added to standard-of-care (SOC), provides clinical benefit to patients with newly diagnosed HGG when compared to historical performance.

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
Mittwoch, April 17, 2024
Research, Infectious Diseases, Neurology, Biotechnology, Other Health, Health, General Health, Other Science, Science, American Academy, GenePeeks, University, Cancer, Foundation Medicine, Genomics, DSM-IV codes, Infection, Bacteria, Fortune 500, Medical laboratory, Clear Labs, NGS, CLIA, Medicine, Encephalitis, UCSF, Ventricular septal defect, Patient, Meningitis, Parasitism, AAN, Physician, Immunodeficiency, Virus, Neuro, Fungus, CSF, Diagnosis, Neoplasm, Cerebrospinal fluid, Metagenomics, Pharmaceutical industry

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

Unleash Your Inner Rockstar at Anthology Together 2024 as Drummer Mark Schulman and Neuro Performance Coach Dr. Heather J. Crider Inspire EdTech Leaders and Students to be Bold and Embrace New Opportunities

Retrieved on: 
Donnerstag, April 25, 2024
Education, Yahoo! Finance, Learning, Fear, Thought, Educational technology, Thrive Global, BOCA, Student, Anxiety, Neuro, Management

The powerhouse team will encourage attendees to be bold, unleash their inner rockstar and embrace new opportunities.

Key Points: 
  • The powerhouse team will encourage attendees to be bold, unleash their inner rockstar and embrace new opportunities.
  • "Mark and Heather's keynote performance is packed with energy and insights focused on taking a fresh approach, thinking differently, and igniting inspiration."
  • Dr. Heather J. Crider is a burnout recovery expert and certified neuro performance coach.
  • AT24 promises a dynamic lineup of inspirational speakers, industry trailblazers, and innovative sessions to inspire and drive progress in higher education.

Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

Retrieved on: 
Donnerstag, April 25, 2024
Cancer, Congress, IMRT, Physics, Cyberknife, Health, Tomotherapy, Software, Patient, University, Royal Marsden Hospital, Radiation therapy, Malignancy, MBA, Neuro, Medical imaging

MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.

Key Points: 
  • MADISON, Wis., April 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024.
  • The European Society for Radiotherapy and Oncology's (ESTRO) annual meeting will take place May 3 to May 7, 2024, in Glasgow, Scotland.
  • Accuray is a wellness focused organization, taking into account the patient's health and well-being throughout their treatment when prioritizing product enhancements.
  • Uniformity in image quality and consistency in Hounsfield units validate their use in this important step in the radiation therapy treatment workflow.

Longtime Mayo Clinic Neurologist Dr. Richard J. Caselli Joins SPARK Neuro as Medical Director

Retrieved on: 
Dienstag, April 16, 2024
Alzheimer's disease, FDA, Mayo Clinic, Bangladesh Technical Education Board, Research, Albert Einstein's brain, Dementia, Clinical professor, Patient experience, Patient, Neurology, Neuro, EEG, Patient satisfaction, Medical director, Medical device

LOS ANGELES, April 16, 2024 /PRNewswire/ -- SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director.

Key Points: 
  • LOS ANGELES, April 16, 2024 /PRNewswire/ -- SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director.
  • With a 35-year career at the Mayo Clinic, Dr. Caselli brings extensive expertise and leadership in neurology and cognitive aging to SPARK Neuro.
  • During his tenure at Mayo Clinic, Dr. Caselli and his team collaborated with SPARK Neuro on several research initiatives funded by the National Institutes of Health.
  • Dr. Caselli's distinguished career includes serving as Chair of the Department of Neurology, Medical Director of Patient Experience, and Director of Research at the Mayo Clinic.

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

Retrieved on: 
Dienstag, April 9, 2024
College, Neurology, Neoplasm, Brain, M.B.A, Utrecht University, Oncology, Neuro, Central nervous system, Novartis, CNS, GBM, Biostatistics, Committee, Biology, Breast, University, Neurosurgery, PSTV, Cancer, Plus, Science park, Doctor of Philosophy, Glioblastoma, Therapy, Texas A&M University, Drug development, Halozyme, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.

Key Points: 
  • Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory.
  • In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
  • Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors.
  • Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research.

NeuroCatch Introduces PeakSelect, Enabling a Deeper Clinical Dive into Brain Vital Signs at a Doctor's Office Near You

Retrieved on: 
Dienstag, April 9, 2024
Research, MD–PhD, Blood pressure, Neurology, Brain, Concussion, Mass General Brigham, Vital signs, Clinical, Neuro, Patient, Mental health, Thermoregulation, MD, Athlete, Medicine, Detroit Lions, Dementia, Sport, ERPs, Medical device

BOSTON, April 9, 2024 /PRNewswire/ -- NeuroCatch Inc., a leading medical device company that enables rapid access to an objective assessment of brain health at the point of care, today announced the release of PeakSelect, an innovative software tool designed to improve clinical decision making. An enhancement to the NeuroCatch Platform, PeakSelect allows users to evaluate specific brain vital sign responses for precision medicine in patients undergoing portable neuro-physiological brain function assessment.

Key Points: 
  • An enhancement to the NeuroCatch Platform, PeakSelect allows users to evaluate specific brain vital sign responses for precision medicine in patients undergoing portable neuro-physiological brain function assessment.
  • "The first of an ongoing cadence of planned software upgrades, PeakSelect enhances the impact of NeuroCatch's brain health vital sign data to inform better clinical decision-making, more robust clinical trials, and more effective training regimes."
  • Through regular, over-the-air updates, NeuroCatch is continually advancing the powerful impact of brain vital sign monitoring for frontline health impacts.
  • "The NeuroCatch platform has already proven itself a breakthrough device with its mobile ability, rapid analysis and sophisticated sensitivity to analyze brain vital sign data.